Eicosanoid synthesis inhibition and renal allograft function during acute rejection

Area of Science:

• Immunology
• Pharmacology
• Nephrology

Background:

• Renal allograft rejection involves significant declines in blood flow, glomerular filtration rate (GFR), and urine output.
• Eicosanoids, including thromboxane B2 (TXB2) and leukotriene B4 (LTB4), play a role in renal allograft dysfunction.
• Understanding the specific pathways involved in rejection is crucial for developing effective treatments.

Purpose of the Study:

• To investigate the effects of the dual cyclooxygenase-lipoxygenase inhibitor BW755C on renal allograft function and rejection in dogs.
• To compare the efficacy of dual inhibition versus selective cyclooxygenase inhibition (indomethacin) on renal allograft outcomes.
• To elucidate the role of eicosanoid metabolism in renal allograft rejection.

Main Methods:

• Anesthetized dogs underwent unilateral renal allotransplantation.
• Animals were treated with either BW755C (dual inhibitor) or indomethacin (selective COX inhibitor).
• Renal blood flow, GFR, urine output, eicosanoid production, cellular infiltration, and tissue damage were assessed over 5 days.

Main Results:

• BW755C treatment maintained renal allograft blood flow and prevented the decline in GFR and urine flow.
• BW755C reduced cellular infiltration and tissue damage in allografts compared to untreated controls.
• Indomethacin did not improve GFR or urine output and reduced allograft blood flow, unlike BW755C.

Conclusions:

• Inhibition of both cyclooxygenase and lipoxygenase pathways effectively improves renal allograft function and reduces tissue damage.
• Selective inhibition of the cyclooxygenase pathway alone does not improve renal allograft function.
• Arachidonate-lipoxygenase metabolites exacerbate renal allograft rejection, highlighting their therapeutic targeting potential.